Drug Profile
GBR 900
Alternative Names: BXL-1H5; GBR-900; MNAC-13Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Lay Line Genomics
- Developer Glenmark Pharmaceuticals S.A.
- Class Analgesics; Monoclonal antibodies
- Mechanism of Action TrkA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Pain(In volunteers) in United Kingdom (Parenteral)
- 01 Nov 2016 Glenmark Pharmaceuticals completes a phase I trial in Pain (In volunteers) in United Kingdom (NCT02235727)
- 04 Jun 2014 Phase-I clinical trials in Pain in United Kingdom (Parenteral)